NEW YORK (TheStreet) -- After rallying higher on Tuesday following positive reports about its cannabinoid epilepsy drug, Epidiolex, shares of GW Pharmaceuticals (GWPH) are lower by roughly 5% on Wednesday after the company announced a secondary offering.
On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said investors want to buy the stock on its secondary offering.
Why? Well, it's simple. Cramer reasoned that GW Pharmaceuticals is the "only really legitimate" marijuana company for investors to put their money in. The British company is also doing very well, he added.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts